Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) (EPITOC)
Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC)
Sponsor: Blokhin's Russian Cancer Research Center
A PHASE2/PHASE3 clinical study on BRCA1 Mutation and BRCA2 Mutation, this trial is ongoing. The trial is conducted by Blokhin's Russian Cancer Research Center and has accumulated 6 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2022 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2_PHASE3
▶ Show 1 earlier version
-
Sep 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Blokhin's Russian Cancer Research Center
For direct contact, visit the study record on ClinicalTrials.gov .